Holen Sie sich die Stockscreener-App
410.97
0.65%
2.181
Schlusskurs vom Vortag:
$408.79
Offen:
$410
24-Stunden-Volumen:
694.46K
Relative Volume:
0.50
Marktkapitalisierung:
$59.21B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-250.41
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
+11.39%
1M Leistung:
+22.20%
6M Leistung:
+108.47%
1J Leistung:
+151.41%
1-Tages-Spanne:
$407.48
$415.75
1-Wochen-Bereich:
$363.96
$415.75
52-Wochen-Spanne:
$157.43
$415.75
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
410.75 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
671.18 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
224.29 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
172.49 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
271.36 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera’s Critical Pivot to Oncology - Nanalyze
RBC Capital raises Natera stock price target on MRD testing growth - Investing.com Canada
RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating - marketscreener.com
Natera, Inc. (NTRA) Stock Price, News, Quote & History - ca.finance.yahoo.com
Natera Inc (NTRA) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 73/100 - GuruFocus
Svetlana Nikic Celebrates Natera’s Signatera Milestone in Japan - Oncodaily
Natera stock gains 2.75 percent after Japan test approval - AD HOC NEWS
Has Natera (NTRA) Run Ahead Of Fair Value After Its Japan Signatera Approval? - simplywall.st
Natera, Inc. (NTRA) stock price, news, quote and history - Yahoo Finance Australia
Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media
Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar - Yahoo Finance
Signatera Surges in Liquid Biopsy Race with New Lung Cancer Data and a Japan Approval - Inside Precision Medicine
Form 144 Natera For: 23 September By Investing.com - Investing.com Canada
Form 144 Natera For: 23 September - Investing.com India
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Yahoo Finance
$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan
Natera, Inc.Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer - marketscreener.com
Why Is Natera (NTRA) Stock Soaring Today - Yahoo Finance
A Look at Natera Inc (NTRA) After 5.5% Gain -- GF Value $219.69 vs Price $390.90 - GuruFocus
Behavioral Patterns of NTRA and Institutional Flows - Stock Traders Daily
Natera Inc stock reaches all-time high at 373.58 USD By Investing.com - Investing.com Nigeria
Natera Inc Stock (NTRA) Moved Up by 5.67% on Sep 22: Facts Behind the Movement - TradingKey
Natera gains as fresh Signatera lung cancer data and upbeat analyst sentiment support shares - Quiver Quantitative
NTRA Looks 68.7% Overvalued on GF Value™ - GuruFocus
Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer - Finviz
Natera’s Signatera Receives Japanese Approval as CDx for Muscle-Invasive Bladder Cancer - GenomeWeb
Natera Inc stock reaches all-time high at 373.58 USD - Investing.com
Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027 - TradingView
A cancer test receives its second Japan approval in three months to guide bladder-cancer treatment. - Stock Titan
Enterprise value to EBITDA ratio of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA.CI - TradingView
Final Trade: Uber, Micron, Natera and Datadog - CNBC
How Lung Cancer Data Will Impact Natera Stock Investors - simplywall.st
Natera, Inc. (NTRA) Stock Analysis: Amidst Rapid Growth, What Lies Ahead for This Diagnostics Leader? - DirectorsTalk Interviews
Natera stock gains as new lung cancer study supports Signatera value - AD HOC NEWS
Natera (NTRA) Study Of 1,100 Patients Supports Signatera In Lung Cancer - simplywall.st
Why Natera (NTRA) Is Up 12.3% After Landmark Lung Cancer MRD Data At IASLC 2026 - Yahoo Finance
Natera (NTRA) Stock Fair Value Rises After Signatera And Guidance Drive Analyst Revisions - Yahoo Finance
Natera CEO Steven Chapman Sells 1,698 Shares for $545,000 - The Motley Fool
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM - Business Wire
Show Me The Money: Natera Delivers Over 120% Gain In Just About A Year - RTTNews
Natera co-founder Sheena sells $3.2m in shares - Investing.com
Natera (NASDAQ: NTRA) co-founder sells 9,150 shares under 10b5-1 plan - Stock Titan
Natera(NTRA.US) Director Sells US$3.22 Million in Common Stock - Moomoo
Natera Inc (NTRA) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 77/100 - GuruFocus
Natera Inc Stock (NTRA) Moved Up by 5.05% on Sep 17: Key Drivers Unveiled - TradingKey
Natera Stock Has Excellent Technical ‘DNA’ as NTRA Sets a New All-Time High - Yahoo Finance
Natera executive chairman Matthew Rabinowitz sells $34.8m in stock - Investing.com
Natera executive chairman Matthew Rabinowitz sells $34.8m in stock By Investing.com - Investing.com Nigeria
Natera (NASDAQ: NTRA) chair unloads stock in preset plan - stocktitan.net
Natera at 2026 Global Healthcare Conference: growth broadens By Investing.com - Investing.com Australia
Natera at 2026 Global Healthcare Conference: growth broadens - Investing.com
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
Sep 15 '26 |
Sale |
350.07 |
6,000 |
2,100,431 |
224,464 |
| Sheena Jonathan | CO-FOUNDER |
Sep 16 '26 |
Sale |
354.19 |
3,150 |
1,115,714 |
221,314 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Sep 15 '26 |
Sale |
347.19 |
50,000 |
17,359,280 |
2,125,394 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Sep 14 '26 |
Sale |
334.76 |
50,000 |
16,737,977 |
2,175,394 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Sep 15 '26 |
Sale |
350.01 |
2,000 |
700,014 |
0 |
0.18%
0.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):